These injections work by mimicking the hormone GLP-1 that your body naturally produces, which helps to slow gastric emptying and increase feelings of fullness
Glucagon-like peptide-1 receptor agonists rank among the most effective medications for lowering blood glucose and body weight, as well as reducing cardiovascular risk in individuals with diabetes
Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial
For semaglutide specifically, patients with kidney dysfunction do not require renal dosing adjustments (Key Considerations in Use of SGLT2 Inhibitors and GLP-1RAs for CV Risk Reduction in Patients with T2D, 2020) Contraindications to GLP-1 agonists include a history of serious hypersensitivity reactions to a GLP-1 agonist, pregnancy, breastfeeding, and a personal or family history of medullary or thyroid cancer or MEN2 (Key Considerations in Use of SGLT2 Inhibitors and GLP-1RAs for CV Risk Reduction in Patients with T2D, 2020)